Disease · MONDO_0019087
Trials226
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 226
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | Phase 1/2 | 407 | 2024-03-20 | Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer | FUTIBATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04083976 | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | Phase 2 | 316 | 2025-02-24 | Advanced Solid Tumor | ERDAFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Phase 1/2 | 216 | 2025-04-02 | Cancer | BEXMARILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | Phase 2 | 208 | 2017-11-20 | Multiple Myeloma, Neoplasms | CETUXIMAB, VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT02989857 | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Phase 3 | 187 | 2022-04-13 | Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | IVOSIDENIB | Its record names the disease | ClinicalTrials.gov |
| NCT03474640 | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Phase 1 | 184 | 2024-11-22 | Advanced Malignancies | TORIPALIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | Phase 2 | 147 | 2023-02-23 | Cholangiocarcinoma | PEMIGATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | 143 | 2022-07-15 | Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | INFIGRATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00789958 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | Phase 2 | 105 | 2016-09-22 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | CAPECITABINE, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00661830 | Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | Phase 2 | 103 | 2013-11-21 | Adenocarcinoma | GEMCITABINE, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | Phase 2 | 86 | 2023-07-11 | Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma | ATEZOLIZUMAB, COBIMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma | Phase 2 | 74 | 2018-05-29 | Cholangiocarcinoma | GEMCITABINE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00033540 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | Phase 2 | 57 | 2012-08-28 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | CAPECITABINE, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00356889 | Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors | Phase 2 | 56 | 2013-05-20 | Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | BEVACIZUMAB, ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00660699 | A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers | Phase 2 | 50 | 2015-05-27 | Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer | DOCETAXEL, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | Phase 3 | 48 | 2024-05-08 | Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | CISPLATIN, GEMCITABINE, INFIGRATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Phase 2 | 47 | 2025-09-25 | Tumor, Solid, Gastrointestinal Cancer | HYDROXYCHLOROQUINE, ULIXERTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00338988 | Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma | Phase 2 | 44 | 2010-12-08 | Cancer of the Gallbladder, Cancer of the Biliary Tract | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03250273 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Phase 2 | 44 | 2021-12-16 | Metastatic Cholangiocarcinoma, Cholangiocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Unresectable Cholangiocarcinoma | ENTINOSTAT, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02053376 | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | Phase 2 | 43 | 2019-01-30 | Metastatic Biliary Tract Carcinoma | REGORAFENIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019087/trials